Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Embecta Corp. (EMBC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.08+0.76 (+3.00%)
At close: 04:00PM EDT
26.08 0.00 (0.00%)
After hours: 04:16PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close25.32
Open25.15
Bid25.00 x 800
Ask30.00 x 900
Day's Range24.16 - 26.19
52 Week Range23.84 - 49.00
Volume578,190
Avg. Volume1,269,527
Market Cap1.507B
Beta (5Y Monthly)N/A
PE Ratio (TTM)3.80
EPS (TTM)6.87
Earnings DateMay 13, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
13% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for EMBC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Embecta Corp.
    EMBC: Lowering target price to $28.00EMBECTA CORP has an Investment Rating of BUY; a target price of $28.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of High; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Investopedia

    Top Healthcare Stocks for July 2022

    These are the healthcare stocks with the best value, fastest growth, and most momentum for July 2022.

  • GlobeNewswire

    Embecta Corp. Reports Second Quarter and First Six Months of Fiscal Year 2022 Financial Results and Provides Financial Guidance for the Last Six Months of Fiscal Year 2022

    PARSIPPANY, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), one of the largest pure-play diabetes care companies in the world following its April 1, 2022, spin off from Becton, Dickinson and Company ("BD"), today reported financial results for the three- and six-month periods which ended March 31, 2022, and provided financial guidance for the last six months of the fiscal year ending September 30, 2022. “Our global team successfully executed the spin off from BD

  • GlobeNewswire

    embecta to Participate in Upcoming Investor Conferences in May

    PARSIPPANY, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will participate in the following upcoming investor conferences: The 2022 RBC Capital Markets Global Healthcare Conference at the Intercontinental NY Barclay Hotel in New York, NY. Management will participate in a fireside chat on Wednesday, May 18 at 9:30 a.m. Eastern Time. The Piper Sandler Ophthalmology and Diabetes Symposium. Management will participate in a virtual fires

Advertisement
Advertisement